Ask about this productRelated genes to: MAOB antibody
- Gene:
- MAOB NIH gene
- Name:
- monoamine oxidase B
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- Xp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: MAOB antibody
Related articles to: MAOB antibody
- This study describes 14 novel D2AAK1 derivatives exhibiting enhanced neuroprotective properties. These derivatives were tested for their inhibitory effects on AChE and MAO-B, as well as their effect on cell viability under normal conditions and under oxidative stress. D2AAK1 derivatives show strong cytoprotective effects, increasing cell viability by up to 80% under normal conditions and up to 60% under oxidative stress. These effects may involve modulation of MAPK p38 and Nrf2 pathway interactions, known to promote antioxidant and anti-apoptotic responses. In vivo studies indicated a beneficial effect of the tested derivative on memory processes in the novel object recognition test. These findings identify D2AAK1 derivatives as promising lead compounds for further development as potential treatments of memory deficits. - Source: PubMed
Publication date: 2026/08/21
Jastrzębski Michał KWójcik PiotrPietrzak-Mitura DianaBartyzel AgataTargowska-Duda Katarzyna MKarcz TadeuszWronikowska-Denysiuk OlgaOlejarz-Maciej AgnieszkaMichalak AgnieszkaSumara AgataDrączkowski PiotrFornal EmiliaWróbel Tomasz MKaczor Agnieszka A - Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are multifactorial diseases that are characterized by several interconnected pathological mechanisms, such as the aggregation of amyloid-beta (Aβ), hyperphosphorylation of tau, accumulation of α-synuclein, oxidative stress, mitochondrial dysfunction, neuroinflammation, and neurotransmitter imbalance. Conventional single-target therapies failed to produce significant clinical effects due to the fact that they target only individual disease pathways. Thus, the multitarget-directed ligand (MTDL) strategy has become an attractive therapeutic option, and MTDLs can act on several pathological targets simultaneously. Recent advances in multitarget drug development for AD and PD targeting compounds targeting Aβ, BACE1, MAO-B, cholinesterases, metal-ion dyshomeostasis, oxidative stress, and inflammatory pathways are reviewed. A few potential candidates, such as GV-971, Prasinezumab, Huperzine A, curcumin derivatives, and hybrids of MAO-B inhibitors, have shown neuroprotective and cognitive effects in preclinical and clinical studies. There are significant advances in the clinical pipeline, with over 180 clinical trials for AD and over 130 clinical trials for PD testing multitarget or disease-modifying strategies. The review also highlights the growing importance of computer-aided drug design (CADD), artificial intelligence (AI), and machine learning (ML) in speeding up the discovery of MTDL, optimizing their pharmacokinetic profiles, and predicting multitarget interactions. However, there are still major obstacles to be overcome, such as the ability to cross the blood-brain barrier, optimizing the pharmacokinetics, the difficulties of transferring from the animal to the human model, and the complexity of the regulatory process. New strategies based on nanomedicine, biomarker-driven trials, personalized medicine, and drug repurposing will enhance therapeutic precision and clinical success. - Source: PubMed
Publication date: 2026/08/31
Khan Azmat UllahAbdullah AbdullahNaqvi Syeda FarwaTahir HadiaKhalid HiraSarfraz HinaKhan Yousaf - var. is a medicinal species whose reported pharmacological effects primarily target the central nervous system, including anxiolytic, antidepressant, and anticonvulsant activities, attributed in part to flavonoids such as tiliroside (). In this study, 14 compounds were isolated and identified from the methanolic extract (Ta-MeOH) and evaluated by molecular docking against the monoamine oxidases MAO-A and MAO-B, enzymes implicated in Parkinson's disease (PD) due to their involvement in dopamine metabolism. Chemical analysis identified six terpenes: α- and β-amyrine (-), β-sitosterol (), stigmasterol (), ursolic acid (), and β-sitosterol glucoside (); the novel diglycosylated monoterpene 4α-terpineol sambubioside (), characterized through its hexaacetate derivative (); the flavonoids tiliroside () and rutin (); sucrose (); and four phenolic compounds: scopoletin () caffeic acid (), coumaric acid (), and chlorogenic acid (). Molecular docking against monoamine oxidases A and B (MAO-A and MAO-B) was used as a computational strategy to prioritize isolated metabolites for biological evaluation. β-Sitosterol glucoside (), 4α-terpineol sambubioside (), tiliroside () and rutin () exhibited the most favorable docking scores toward MAO-B, with predicted binding energies of -10.8733, -11.1434, -12.16986 and -12.9474 kcal/mol, respectively. Considering the docking results together with phytochemical and experimental criteria, () and () (1 mg/kg) were prioritized for biological evaluation, together with Ta-MeOH extract (100 mg/kg) and selected fractions (25 mg/kg), in a reserpine-induced mouse model of parkinsonism using L-DOPA (150 mg/kg) as a positive control. In the open field test, spontaneous locomotor activity was assessed by total crossings and expressed as AUC. Ta-MeOH significantly increased locomotor activity compared with the reserpine-treated group (AUC: 1281.8 vs. 551.7, respectively; < 0.05). Tiliroside () also increased locomotor activity (AUC: 858). In the Rota-Rod test, fine motor coordination was assessed by latency to fall and expressed as AUC. Ta-MeOH showed the greatest recovery, with AUC values of 431, 89, and 34 at 4, 10, and 20 rpm, respectively. In addition, treatments derived from attenuated behavioral alterations induced by reserpine in the Irwin test. Overall, this study demonstrates that integrating phytochemical isolation, molecular docking, and in vivo pharmacological evaluation provides a useful strategy for prioritizing bioactive metabolites from . These findings support further pharmacological investigation of this medicinal species and its isolated metabolites, while additional studies are required to establish their molecular targets and mechanisms of action. - Source: PubMed
Publication date: 2026/08/17
Osorio-García MaribelJiménez-Aparicio Antonio RupertoHerrera-Ruiz MaribelJiménez-Ferrer EnriqueZamilpa AlejandroDomínguez-Mendoza Blanca EdaTrejo-Tapia GabrielaGonzález-Cortazar Manasés - COVID-19 remains a relevant area of biomedical investigation because its pathogenesis involves complex virus-host interactions. This study aimed to explore, through purely in silico and hypothesis-generating insights, the predicted molecular associations between benzyl isothiocyanate (BITC) from and COVID-19-associated host-response pathways. BITC-associated targets were collected from compound-target databases, while COVID-19-associated targets were obtained from disease-gene databases and transcriptomic datasets. Overlapping targets were analyzed using protein-protein interaction network construction, hub-gene prioritization, Gene Ontology and KEGG enrichment analyses, and molecular docking. A total of 271 unique BITC-associated targets and 1890 COVID-19-associated targets were identified, with 36 candidate targets overlapping. PPI analysis generated a connected network of 24 nodes and 39 edges. Hub-gene analysis prioritized ACE, JUN, MAOA, CDK1, MAOB, HCK, CCNA2, ACHE, GADD45A, and ADRA2A. Enrichment analysis indicated associations with inflammatory response, vascular regulation, calcium homeostasis, monoamine oxidase activity, NF-κB signaling, serotonergic synapse, and tryptophan metabolism. Validated active-site docking of six targets yielded comparative Vina scores ranging from -5.380 to -6.437 kcal/mol. These preliminary findings provide theoretical target-pathway associations supporting further investigation of BITC as a potential immunomodulatory candidate within COVID-19-related host-response pathways. - Source: PubMed
Publication date: 2026/08/21
Sumague Terrence SuministradoAziz Ibrahim MAljowaie Reem MAlsaleh Asma NAlkubaisi Noorah AAlmajhdi Fahad N - A progressive neurodegenerative disease, Alzheimer's Disease (AD), is typified by cognitive decline, synaptic malfunction, and permanent death of neurons. It has a complicated etiology that includes oxidative stress, neuroinflammatory cascades, and monoamine oxidase dysregulation; therapies are limited in their long-term efficacy. This highlights the necessity for carefully crafted multi-target medicines that can modulate multiple pathogenic pathways at once. The advantageous electronic characteristics and structural flexibility of thiazole and benzothiazole derivatives make them appealing, as they can penetrate the blood-brain barrier and serve as heterocyclic scaffolds in medicinal chemistry. According to recent studies, thiazole-based drugs have a strong inhibitory effect against butyrylcholinesterase and acetylcholinesterase, increasing the availability of acetylcholine in synapses. Monoamine oxidase-B (MAO-B) is also strongly and selectively inhibited by several derivatives, which helps to lower oxidative stress and promote neuroprotection. Significantly affecting enzyme affinity, selectivity, and multitarget engagement are structural alterations such as halogen substitution, methoxy incorporation, hydrazone connections, and sulfonamide or piperazine moieties. Beyond enzyme modulation, thiazole-containing molecules interfere with Aβ aggregation, disrupt β-sheet fibril formation, and demonstrate antioxidant and metal-chelating properties. These combined biological effects position thiazole derivatives as potentially disease-modifying multitarget- directed ligands. According to an analysis of the evaluated research, the most effective anti- Alzheimer effects were found in thiazole and benzothiazole derivatives with halogen, methoxy, hydrazone, piperazine, and sulfonamide substituents. Many substances showed nanomolar to low micromolar inhibition of AChE, BuChE, and MAO-B while concurrently inhibiting oxidative stress and amyloid-β formation. Studies on the structure-activity link have shown how crucial strategic substitution patterns are for improving potency, selectivity, and multitarget engagement. This research highlights the feasibility of using thiazoles as scaffold pharmacophores for developing novel drugs to treat Alzheimer's disease and provides vital guidance on the development of future drugs. This review is a comprehensive compilation of small thiazoles being studied for AD with emphasis on structure-activity relationships, molecular targets, and multitarget therapies. This review provides useful information for the rational design of next-generation anti-Alzheimer drugs. It highlights prospective directions for future drug discovery research by methodically outlining current achievements in thiazole-derived AChE, BuChE, MAO-B, and amyloid-β inhibitors. - Source: PubMed
Publication date: 2026/08/13
Chaudhary GeetanjaliPaliwal DeepikaThakur AmanGulati Harmandeep KaurKaushik NiranjanYadav Ashish